Alphatec Holdings, Inc. (NASDAQ:ATEC) Given Average Rating of “Moderate Buy” by Brokerages

Shares of Alphatec Holdings, Inc. (NASDAQ:ATEC) have received an average rating of “Moderate Buy” from the nine ratings firms that are covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell rating and eight have given a buy rating to the company. The average 1 year target price among brokers that have updated their coverage on the stock in the last year is $18.25.

ATEC has been the subject of a number of recent research reports. Wells Fargo & Company boosted their target price on Alphatec from $14.00 to $16.00 and gave the stock an “overweight” rating in a research report on Thursday, October 16th. Canaccord Genuity Group reissued a “buy” rating and set a $20.00 price objective on shares of Alphatec in a report on Friday, August 1st. Weiss Ratings reissued a “sell (d-)” rating on shares of Alphatec in a report on Tuesday, October 14th. JPMorgan Chase & Co. assumed coverage on shares of Alphatec in a research note on Friday. They set an “overweight” rating and a $19.00 price target for the company. Finally, Barclays reissued an “overweight” rating and set a $22.00 price target (up from $21.00) on shares of Alphatec in a research note on Monday, August 4th.

Insiders Place Their Bets

In related news, Director Mortimer Berkowitz III sold 62,500 shares of the company’s stock in a transaction dated Tuesday, September 9th. The stock was sold at an average price of $15.97, for a total value of $998,125.00. Following the completion of the sale, the director owned 618,050 shares in the company, valued at approximately $9,870,258.50. This represents a 9.18% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, EVP Craig E. Hunsaker sold 10,876 shares of the company’s stock in a transaction dated Wednesday, August 6th. The shares were sold at an average price of $15.33, for a total value of $166,729.08. Following the completion of the sale, the executive vice president directly owned 1,389,142 shares of the company’s stock, valued at approximately $21,295,546.86. This trade represents a 0.78% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 780,575 shares of company stock valued at $11,769,527 in the last ninety days. 20.90% of the stock is currently owned by insiders.

Institutional Trading of Alphatec

A number of large investors have recently made changes to their positions in ATEC. Wealth Enhancement Advisory Services LLC increased its position in shares of Alphatec by 301.0% in the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 59,987 shares of the medical technology company’s stock valued at $608,000 after buying an additional 45,027 shares in the last quarter. Oppenheimer Asset Management Inc. increased its holdings in shares of Alphatec by 13.4% in the first quarter. Oppenheimer Asset Management Inc. now owns 13,144 shares of the medical technology company’s stock worth $133,000 after acquiring an additional 1,552 shares in the last quarter. Western Wealth Management LLC increased its holdings in shares of Alphatec by 9.6% in the first quarter. Western Wealth Management LLC now owns 87,050 shares of the medical technology company’s stock worth $883,000 after acquiring an additional 7,614 shares in the last quarter. Lisanti Capital Growth LLC bought a new stake in shares of Alphatec in the first quarter worth about $3,521,000. Finally, Teacher Retirement System of Texas bought a new stake in Alphatec during the 1st quarter worth approximately $158,000. Institutional investors own 66.35% of the company’s stock.

Alphatec Stock Performance

Alphatec stock opened at $16.11 on Friday. The stock has a 50-day simple moving average of $15.17 and a 200 day simple moving average of $12.98. The company has a quick ratio of 1.77, a current ratio of 2.88 and a debt-to-equity ratio of 23.22. Alphatec has a 12-month low of $5.18 and a 12-month high of $16.70. The stock has a market capitalization of $2.38 billion, a price-to-earnings ratio of -14.26 and a beta of 1.05.

Alphatec (NASDAQ:ATEC) last announced its earnings results on Thursday, July 31st. The medical technology company reported $0.02 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.06) by $0.08. The company had revenue of $185.54 million during the quarter, compared to the consensus estimate of $178.85 million. During the same period in the prior year, the firm posted ($0.29) earnings per share. The company’s revenue was up 27.5% on a year-over-year basis. Alphatec has set its FY 2025 guidance at EPS. On average, research analysts anticipate that Alphatec will post -1.08 earnings per share for the current fiscal year.

About Alphatec

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.